AlphaFold predicted structure
MTAP · Q13126

Mean pLDDT
92.7/ 100
Very high
283 residues
Confidence breakdown
- Very high(≥ 90)83%
- Confident(70–90)11%
- Low(50–70)3%
- Very low(< 50)2%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
methylthioadenosine phosphorylase
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
Sarcoma cancer susceptibility
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownSarcoma susceptibility
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownChildhood solid tumours
Monogenic hearing loss
Skeletal dysplasia
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinteddiaphyseal medullary stenosis-bone malignancy syndrome
Diaphyseal medullary stenosis - bone malignancy
melanoma
cutaneous melanoma
coronary artery disorder
lung adenocarcinoma
coronary atherosclerosis
non-small cell lung carcinoma
melanocytic nevus
skin cancer
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
S-methyl-5'-thioadenosine phosphorylase
Catalyzes the phosphorolytic cleavage of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose1-phosphate (PubMed:3091600, PubMed:8687427, PubMed:10404592). Involved in the breakdown of MTA, a major by-product of polyamine biosynthesis (PubMed:3091600, PubMed:8687427, PubMed:10404592). Responsible for the first step in the methionine salvage pathway after MTA has been generated from S-adenosylmethionine (PubMed:3091600, PubMed:8687427, PubMed:10404592). Has broad substrate specificity with 6-aminopurine nucleosides as preferred substrates (PubMed:10404592)
MTAP · Q13126

Mean pLDDT
92.7/ 100
Very high
283 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0